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Abstract
 
HIV-1 replication is markedly upregulated in alveolar macrophages (AM) during pulmonary
tuberculosis (TB). This is associated with loss of an inhibitory CCAAT enhancer binding pro-
tein 
 
 
 
 (C/EBP
 
 
 
) transcription factor and activation of nuclear factor (NF)-
 
 
 
B. Since the cellu-
lar immune response in pulmonary TB requires lymphocyte–macrophage interaction, a model
system was developed in which lymphocytes were added to AM. Contact between lympho-
cytes and AM reduced inhibitory C/EBP
 
 
 
, activated NF-
 
 
 
B, and enhanced HIV-1 replica-
tion. If contact between lymphocytes and macrophages was prevented, inhibitory C/EBP
 
 
 
 ex-
pression was maintained and the HIV-1 long terminal repeat (LTR) was not maximally
stimulated although NF-
 
 
 
B was activated. Antibodies that cross-linked macrophage expressed
B-7, and vascular cell adhesion molecule and CD40 were used to mimic lymphocyte contact.
All three cross-linking antibodies were required to abolish inhibitory C/EBP
 
 
 
 expression.
However, the HIV-1 LTR was not maximally stimulated and NF-
 
 
 
B was not activated. Max-
imal HIV-1–LTR stimulation required both lymphocyte-derived soluble factors, and cross-
linking of macrophage expressed costimulatory molecules. High level HIV-1–LTR stimulation
was also achieved when IL-1
 
 
 
, IL-6, and TNF-
 
 
 
 were added to macrophages with cross-
linked costimulatory molecules. Contact between activated lymphocytes and macrophages is
necessary to down-regulate inhibitory C/EBP
 
 
 
, thereby derepressing the HIV-1 LTR.
Lymphocyte-derived cytokines activate NF-
 
 
 
B, further enhancing the HIV-1 LTR.
Key words: infection • cellular immunity • costimulatory molecules • transcription factors • 
derepression
 
Introduction
 
Worldwide, 1.86 billion persons are infected with 
 
Myco-
 
bacterium tuberculosis 
 
and 8% of all tuberculosis (TB)
 
*
 
 cases
occur in persons coinfected with HIV. There is a synergistic
interaction between HIV-1 and 
 
M. tuberculosis. 
 
HIV-1 in-
fection predisposes to activation of latent TB and accelerates
the clinical course of the disease. Conversely, recent studies
also demonstrate that TB accelerates the course of AIDS. In
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Abbreviations used in this paper:
 
 AM, alveolar macrophages; BAL, bron-
choalveolar lavage; CAT, chloramphenicol acetyltransferase; C/EBP
 
 
 
,
CCAAT enhancer binding protein 
 
 
 
; EMSA, electrophoretic mobility
shift assay; LTR, long terminal repeat; NF, nuclear factor; NRE, negative
regulatory element; TB, tuberculosis; VCAM, vascular cell adhesion mol-
ecule; VLA, very late antigen. 
496
 
Contact and Cytokines Are Needed for Maximal HIV Replication
 
the absence of an opportunistic infection, there is little or
no viral replication in the lung even in patients with ad-
vanced AIDS (1). TB markedly increases HIV-1 replication
and mutation in involved lung segments (2). Macrophages
are the major cell type in which HIV-1 replication occurs
in patients with opportunistic infections including TB (3).
Activation of HIV-1 replication during opportunistic in-
fection may underlie the increased mortality observed in
patients coinfected with HIV-1 and TB (4).
The CCAAT enhancer binding protein 
 
 
 
 (C/EBP
 
 
 
)
gene is the predominant C/EBP isoform expressed in alve-
olar macrophages (AM) (5). C/EBP
 
 
 
 has a stimulatory
37-kD isoform and an inhibitory 16-kD isoform. The inhibi-
tory isoform is dominant–negative, repressing promoters
with C/EBP sites when expressed at 20% of the level of the
stimulatory 37-kD isoform (6). Multiple regulators of in-
flammation such as TNF-
 
 
 
 have C/EBP sites in their pro-
moters (7). The serum response factor, a global activator of
inflammation, is also suppressed by inhibitory C/EBP
 
 
 
 (8),
which leads to the hypothesis that this dominant–negative
transcription factor is responsible for maintaining AM in
their baseline quiescent state.
The C/EBP family of transcription factors is essential for
HIV-1 replication in macrophages but not in lymphocytes
(9). There are three C/EBP binding sites present in the
negative regulatory element (NRE) of the HIV-1 long ter-
minal repeat (LTR) (10). AM from normal lung strongly
express an inhibitory 16-kD C/EBP
 
 
 
 transcription factor
that represses the HIV-1–LTR activity in model systems
(11). AM from lung segments involved with TB lose ex-
pression of inhibitory 16-kD C/EBP
 
 
 
, which raises the
possibility that derepression is needed before the HIV-1
LTR can be maximally stimulated. Activation of the 5
 
 
 
HIV-1–LTR promoter is an essential step in the viral life
cycle. The nuclear factor (NF)-
 
 
 
B binding site in the HIV-1
LTR is essential for promoter activity and leads to tran-
scriptional induction of viral replication in both lympho-
cytes and macrophages (12, 13).
In vitro infection of macrophages with 
 
M. tuberculosis
 
fails to reproduce loss of the inhibitory 16-kD C/EBP
 
 
 
isoform, or the increase in HIV-1 replication, observed in
involved lungs of AIDS patients with TB (14). Allogeneic
lymphocytes are able to increase HIV-1 replication in mac-
rophages (15). Further, isolated membranes from activated
lymphocytes enhance HIV-1 replication in macrophages
(16). Because cell-mediated immunity requires interaction
between lymphocytes and macrophages, we hypothesized
that activated lymphocytes were essential to reproduce
macrophage activation observed in vivo. We found that
lymphocyte contact was required to down-regulate inhibi-
tory C/EBP
 
 
 
, and that soluble factors activated NF-
 
 
 
B.
Both contact and soluble factors were required for maximal
HIV-1–LTR induction.
 
Materials and Methods
 
Study Population. 
 
We performed bronchoscopy on two pa-
tients with stable HIV infection without pulmonary disease (see
 
Fig. 2, Patients 6 and 7) and 1 HIV-1–infected patient with ac-
tive pulmonary TB (see Fig. 2, Patient 5). The TB patient had
unilateral segmental infiltrates. Radiographically uninvolved
lobes were identified and a separate bronchoalveolar lavage
(BAL) was performed and processed from these segments. The
BAL protocol was approved by the Human Subjects Review
Committees of New York University Medical Center and
Bellevue Hospital Center, and was performed as described (2).
BAL cells were centrifuged, resuspended in RPMI 1640 (Bio-
Whittaker) with 10% FCS (Life Technologies), and allowed to
adhere to plastic plates for 3 h. Cells were recovered by gentle
scraping with a rubber policeman. AM were 95% pure by mor-
phology and nonspecific esterase staining. HIV-1 viral loads
were quantitated by RT-PCR assay (AMPLICOR HIV-1
Monitor™ Test; Roche Molecular Systems).
 
Immunohistochemistry. 
 
We used autopsy (see Fig. 1, Patients
1, 2, and 4) or transbronchial lung biopsy samples (see Fig. 1, Pa-
tient 3) from HIV patients coinfected with TB. Patient 1 was
dead of miliary TB, acute renal failure, and pulmonary edema.
Patient 2 was dead of miliary TB, and hilar and mediastinum
lymph node TB. Specimens were fixed in periodate/lysine/
paraformaldehyde at 4
 
 
 
C for 10 h. Fixed specimens were dehy-
drated with sucrose gradient and embedded in Histofine Sim-
plestain (Nichirei), frozen in liquid nitrogen, and sectioned (5
 
 
 
m thickness) using a cryostat. Nonspecific staining was blocked
with 10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin,
0.05% (vol/vol) Tween 20, and pH 8.0, for 30 min at room tem-
perature. After washing with TBS, one of the following primary
antibodies was applied: anti–C/EBP
 
 
 
 rabbit and anti–NF-
 
 
 
B
polyclonal antibody (1:100; Santa Cruz Biotechnology, Inc.) or
anti-CD68 monoclonal (1:100; Dako). After incubating for 1 h at
room temperature, sections were washed in TBS four times and
incubated with peroxidase-labeled anti–rabbit or anti–mouse an-
tibody (Histofine Simplestain Max PO; Nichirei) for 30 min at
room temperature. Peroxidase activity was detected with diami-
nobenzidine (DAB; Sigma-Aldrich). Sections were counter-
stained with hematoxylin and dehydrated.
 
Purification and Activation of T Lymphocytes. 
 
PBMC were pu-
rified over Ficoll-Hypaque (Amersham Pharmacia Biotech) sedi-
mentation. T lymphocytes were separated by nylon wool (Rob-
bins Scientific Corp.). The purity of T lymphocytes was more
than 90% by flow cytometry (FACScan
 
®
 
; Becton Dickinson) us-
ing FITC–anti-CD3 antibodies (Becton Dickinson). To obtain
CD4
 
 
 
 or CD8
 
 
 
 T lymphocytes, the Rosettesep (StemCell Tech-
nologies Inc.) was used for negative selection. The purity of
CD4
 
 
 
 or CD8
 
 
 
 lymphocytes was more than 95% by flow cy-
tometry (FACScan; Becton Dickinson) using PE–anti-CD4 or
PE–anti-CD8 antibodies (Becton Dickinson). T lymphocytes
were activated by Con A (Amersham Pharmacia Biotech), 2.5
 
 
 
g/ml, or anti–human CD3
 
 
 
 antibodies (R&D Systems), 5 
 
 
 
g/
ml, for 48 h as described.
 
Blocking of T Lymphocytes and Cross-linking of Antibodies.
 
Where indicated, Con A– (or anti-CD3–) activated T cells were
pretreated with culture medium containing anti-CD28 antibodies
(25 
 
 
 
g/ml), anti-CD40 ligand (CD154) antibodies (25 
 
 
 
g/ml),
and anti–very late antigen (VLA)-4 (CD49
 
 
 
) antibodies (25 
 
 
 
g/
ml) (R&D Systems) for 60 min at 4
 
 
 
C before coculture with
THP-1 cells or AM. For cross-linking assays, protein A/G agarose
beads (100 
 
 
 
l; Santa Cruz Biotechnology, Inc.) were mixed with
anti–B7-1 (CD80) antibodies (25 
 
 
 
g/ml), anti–B7-2 (CD86) an-
tibodies (25 
 
 
 
g/ml), anti-CD40 antibodies (25 
 
 
 
g/ml), and anti–
vascular cell adhesion molecule (VCAM)-1 (CD106) antibodies
(25 
 
 
 
g/ml) (R&D Systems), or control goat serum (Santa Cruz 
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Biotechnology, Inc.) for 60 min at 4
 
 
 
C. These were then added to
culture medium and incubated for 48 h.
 
Cell Culture and Cytokines. 
 
THP-1 cells (TIB-202; Ameri-
can Type Culture Collection) or BF24 cells (AIDS Research and
Reference Reagent Program #1296) were cultured in RPMI
1640 with 10% FCS. Cells were differentiated with 20 ng/ml
PMA (Sigma-Aldrich) for 24 h and incubated with IFN-
 
 
 
 (Bio-
source International) at 1 U/ml for 48 h after PMA treatment.
Where noted, activated T lymphocytes and AM or THP-1 cells
were separated by 0.4 
 
 
 
m pore cell culture insert (Millipore). IL-
1
 
 
 
, IL-6, and TNF-
 
 
 
 in cell culture supernatants from insert ex-
periments were measured by ELISA (R&D Systems). Cloned and
purified IL-1
 
 
 
, IL-6, and TNF-
 
 
 
 (R&D Systems) were added to
BF-24 cells for 48 h before chloramphenicol acetyltransferase
(CAT) measurement.
 
Cell Extract Preparation. 
 
Cells were washed twice in PBS
(Bio-Whittaker). Whole cell extracts were prepared for immuno-
blot analysis by incubation in NP-40 buffer (0.5% NP-40, 10%
glycerol, 0.1 mM EDTA, 20 mM Hepes [pH 7.9], 10 mM NaF
10 mM NaPpi, 300 mM NaCl, 3 
 
 
 
g/ml aprotinin, 2 
 
 
 
g/ml leu-
peptin, 2 
 
 
 
g/ml pepstatin, 1 mM DTT, 1 mM PMSF, and 1 mM
Na
 
3
 
VO
 
4
 
) for 30 min on ice with vigorous shaking. Nuclear ex-
tracts were prepared by NP-40 lysis (buffer A: 10 mM Hepes-
KOH [pH 7.8], 10 mM KCl, 0.1 mM EDTA [pH 8.0], 0.1%
NP-40, 3 
 
 
 
g/ml aprotinin, 2 
 
 
 
g/ml leupeptin, 2 
 
 
 
g/ml pepsta-
tin, 1 mM DTT, 1 mM PMSF, and 1 mM Na
 
3
 
VO
 
4
 
) and incuba-
tion of recovered nuclei in high salt buffer (buffer C: 10 mM
Hepes-KOH [pH 7.8], 420 mM KCl, 0.1 mM EDTA [pH 8.0], 5
mM MgCl
 
2
 
, 2% glycerol, 3 
 
 
 
g/ml aprotinin, 2 
 
 
 
g/ml leupeptin,
2 
 
 
 
g/ml pepstatin, 1 mM DTT, 1 mM PMSF, and 1 mM
Na
 
3
 
VO
 
4
 
). Where indicated, we added 20 
 
 
 
g/ml calpain inhibitor
(Sigma-Aldrich) into NP-40 buffer, buffer A, or buffer C before
cell extraction. Pierce BCA reagents were used to determine ex-
tract protein concentrations. Protein extracts for chloramphenicol
acetyl transferase CAT ELISA (Roche Molecular Biochemicals)
were processed according to manufacturer’s instructions.
 
Immunoblots. 
 
Proteins were separated by SDS-PAGE (Bio-
Rad Laboratories) as described previously (11), and then probed
with antibodies against anti-C/EBP
 
 
 
, followed by visualization
with anti–rabbit HRP antibodies (Santa Cruz Biotechnology,
Inc.) and ECL plus (Amersham Pharmacia Biotech).
 
Electrophoretic Mobility Shift Assays (EMSA). 
 
The DNA
probe used for C/EBP EMSA is the HIV-1 LTR NRE (11). The
NF-
 
 
 
B probe was TGGGCT
 
GGGGAATCCC
 
GCTAA with
bold letters denoting the NF-
 
 
 
B binding domain. The DNA
probe was labeled with [
 
 
 
32
 
P]ATP using T4 polynucleotide ki-
nase in an end-labeling reaction. Full-length reaction products
were isolated and 10
 
5
 
 cpm-labeled DNA mixed with 10 
 
 
 
g of
protein extract, 2.5 
 
 
 
g poly dI/dC, and gel mobility shift buffer.
For supershift experiments, 1–2 
 
 
 
g of antibody was added to the
reaction (anti-C/EBP
 
 
 
, anti–NF-
 
 
 
B p65, or anti–NF-
 
 
 
B p50
antibodies; Santa Cruz Biotechnology, Inc.). Within the experi-
ments, each binding reaction included a constant amount of ex-
tract protein. The DNA–protein complexes were electrophoresed
on a 6% polyacrylamide (Bio-Rad Laboratories) gel at 4
 
 
 
C with
20 mM Tris-borate, pH 8.3, and 0.4 mM EDTA buffer. Images
were produced by a PhosphorImager (Molecular Dynamics).
 
Results
 
Transcription Factor Expression and HIV-1 Replication in
Pulmonary TB.
 
To test if BAL accurately reflects what is
occurring in the lung, immunohistochemistry using anti-
 
bodies to C/EBP
 
 
 
, NF-
 
 
 
B p65, and HIV-1 p24 antigen
was performed on lung sections obtained from normal and
TB patients, with and without HIV-1 infection. Lung sec-
tions from TB patients included regions involved and unin-
volved with TB.
C/EBP
 
 
 
 was strongly expressed in the nucleus and cy-
toplasm of macrophages of normal lung, as demonstrated
by immunoperoxidase staining of macrophages (Fig. 1
 
 
 
A).
Scoring of 154 AM from normal lung demonstrated 64
(41%) C/EBP
 
  
 
with strong nuclear staining. The unin-
volved lung segments of an HIV-1–TB-coinfected patient
also showed strong C/EBP
 
 
 
 expression in AM (Fig. 1
 
 
 
B).
Scoring of 116 AM from uninvolved lung demonstrated
39 (33%) C/EBP
 
  
 
with strong nuclear staining. Near sites
of granulomatus inflammation, AM lost nuclear expression
of C/EBP
 
 
 
 expression. Only 3 out of 116 (3%) of AM
from patient 1 (Fig. 1
 
 
 
C), and 1 out of 21 (5%) AM from
patient 2 (Fig. 1
 
 
 
D), expressed nuclear C/EBP
 
 
 
. There
was cytoplasmic C/EBP
 
 
 
 staining in AM from the in-
volved lung segment (Fig. 2
 
 
 
C) and in type II pneu-
mocytes (unpublished data).
NF-
 
 
 
B p65 had a markedly different pattern of expres-
sion. In normal and uninvolved lung segments of patients
with TB, there was little or no binding of antibody to the
lung (Fig. 1 E). In normal lung, 0 out of 43 (0%) AM ex-
pressed NF-
 
 
 
B, whereas only 3 out of 104 (3%) AM from
an uninvolved lung expressed NF-
 
 
 
B. Lung segments in-
volved with TB had increased nuclear NF-
 
 
 
B p65 staining
in both lymphocytes and macrophages (Fig. 1
 
 
 
F). In in-
volved lung segments, 105 out of 192 cells (55%) from pa-
tient 1, and 123 out of 181 cells (68%) from patient 2, ex-
pressed NF-
 
 
 
B. The identity of AM was confirmed by
anti-CD 68 staining in serial sections. The presence of my-
cobacteria was confirmed by numerous acid-fast bacilli in
the alveolar space (unpublished data).
HIV-1 p24 was expressed in and around areas of granu-
lomatous inflammation (Fig. 1 G). Only epithelioid mac-
rophages (Fig. 1
 
 
 
H, arrows) demonstrated positive im-
munostaining. Multinucleated cells, dendritic cells, and
lymphocytes, had no detectable staining for p24 (unpub-
lished data). The blood lymphocytes in areas of pulmonary
hemorrhage and normal pulmonary parenchyma from two
patients did not stain with anti-p24 antibody. The distribu-
tion of anti-p24 immunostaining was markedly different in
the lymph node samples where dendritic cells were the
predominant cell type, staining with anti-p24 antibody
(unpublished data). There was no background staining in
either the lung or lymph node.
 
Lymphocyte Contact Is Required for Loss of Inhibitory
C/EBP
 
 
 
 in AM. 
 
Similar to our previously reported results
(11), BAL cells obtained from an uninvolved lobe of an
HIV-1–infected patient with TB, strongly expressed in-
hibitory 16-kD C/EBP
 
 
 
 (Fig. 2 A, lane 1), whereas BAL
cells from involved lung segments did not have inhibitory
16-kD C/EBP
 
 
 
 expression (Fig. 2 A, lane 7). The addi-
tion of allogenic lymphocytes stimulated with Con A to
AM preparations from the uninvolved lung, abolished in-
hibitory C/EBP
 
 
 
 expression over 4 d (Fig. 2 A, lane 3). 
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When resting syngenic blood lymphocytes were added
to the AM, there was stable expression of inhibitory
C/EBP
 
 
 
 after 4 d in culture (Fig. 2 A, lanes 4 and 5).
This demonstrates that alteration of C/EBP
 
 
 
 expression
was not an artifact of cell culture. Therefore, with regard
to C/EBP
 
 
 
 expression, the addition of activated lympho-
cytes to AM from uninvolved lung, reproduced the state
of activation found in AM from lung segments involved
with TB.
To test if lymphocyte contact was required to produce
loss of inhibitory C/EBP
 
 
 
, lymphocytes and AM were
separated by a porous 0.4-
 
 
 
m insert. In the absence of di-
 
rect contact, Con A–activated lymphocytes did not re-
duce inhibitory C/EBP
 
 
 
 expression in AM (Fig. 2
 
 
 
A,
lane 6). Similar results were obtained when allogenic lym-
phocytes, stimulated to produce soluble factors by MHC
incompatibility, were added to the upper chamber of the
insert and macrophages were cocultured in the lower
chamber (unpublished data). These data suggest that the
loss of inhibitory C/EBP
 
 
 
 expression in AM requires
lymphocyte contact.
We next tested if activated lymphocytes could stimulate
HIV-1 replication in AM isolated from AIDS patients with
no lung disease. These cells had been provirally infected in
Figure 1. Transcription factor and HIV-1
p24 expression in the lung using immunohis-
tochemistry. (A) Immunoperoxidase stain-
ing of normal lung with C/EBP  polyclonal
antibody. (B) Immunoperoxidase staining of
uninvolved lung of an HIV-1–TB-coin-
fected patient with C/EBP  polyclonal an-
tibody (1,000 ). (C) Involved lung seg-
ment of the same HIV-1–TB patient with
C/EBP  polyclonal antibody (1,000 ).
(D) Involved lung segment from a second
HIV-1–TB patient with C/EBP  poly-
clonal antibody (200 ). (E) Uninvolved
lung segment of an HIV-1–TB coinfected
patient with p65 NF- B immunoperoxi-
dase staining (1,000 ). (F) Involved lung
segment of an HIV-1–TB coinfected pa-
tient with p65 NF- B immunoperoxidase
staining (1,000 ). (G) HIV-1 p24 immu-
noperoxidase staining of a transbronchial
lung biopsy (400 ). (H) HIV-1 p24 immu-
noperoxidase staining of a lung section of
HIV-1– TB involved lung (1,000 ). 
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vivo and therefore contained variable amounts of HIV-1.
The addition of allogenic lymphocytes from an HIV-1–
negative donor enhanced HIV-1 replication in AM prepa-
rations from two HIV-1–infected patients (Fig. 2
 
 
 
B, com-
pare lane 1 with lanes 2–4, and lane 5 with lanes 6 and 7).
Increasing levels of HIV-1 production correlated with the
loss of inhibitory C/EBP
 
 
 
 expression in this system.
We have observed that THP-1 cells differentiated with
PMA and treated with IFN-
 
 
 
 are similar to AM, and we
have used this model system to investigate the mechanisms
controlling HIV-1 replication in macrophages (11, 14). We
used EMSA with the HIV-1 LTR NRE to measure
C/EBP binding activity in the THP-1 extracts. In differen-
tiated THP-1 cells there is a single DNA protein complex
that competes with excess unlabeled NRE oligonucleotide
(Fig. 3
 
 
 
A, compare lanes 1 and 2). The addition of IFN-
 
 
 
leads to the induction of another specific, rapidly migrating
NRE–protein complex (Fig. 3
 
 
 
A, lanes 3 and 4). Con
A–activated lymphocytes produce loss of the rapidly mi-
grating NRE–protein complex over 2 d (Fig. 3 A, lanes 5–8).
Supershift with antibody to C/EBP
 
 
 
 demonstrates that
both the NRE–protein complexes contain C/EBP
 
 
 
 (Fig. 3
A, lane 10). A minor rapidly migrating NRE–protein com-
 
plex is unmasked by the supershift reaction, whereas
C/EBP
 
 
 
 contributes over 90% of the NRE binding activ-
ity in this system.
Western blotting assessed expression of both C/EBP
 
 
isoforms. Activated lymphocytes down-regulate inhibitory
C/EBP  expression in THP-1 macrophages (Fig. 3  B,
lanes 1–3). When the activated lymphocytes and macro-
phages are separated by a 0.4- m insert, inhibitory C/EBP 
expression is increased (Fig. 3 B, lanes 4–6). These data
support using THP-1 cells treated with PMA and IFN-  as
a model for AM, and demonstrate that contact between
lymphocytes and macrophages is required for loss of inhib-
itory C/EBP  in this model system. We then tested the
ability of purified CD4 and CD8 lymphocyte subsets to
down-regulate inhibitory C/EBP . Surprisingly, both acti-
vated CD4  and CD8  lymphocytes were able to down-
regulate inhibitory C/EBP  (Fig. 3 C, lanes 2 and 4). In
addition, the CD 8  lymphocytes abolished stimulatory
C/EBP  expression (Fig. 3 C, lane 4). To address the pos-
sibility that production of the inhibitory 16 kD is due to
calpain-mediated proteolytic cleavage (17), we repeated
these experiments with a calpain inhibitor (18). The addi-
tion of calpain inhibitor did not lead to significant change
in the expression of 16-kD C/EBP  in whole cell extracts
(Fig. 3 D, compare lanes 1 and 2) or nuclear extracts (Fig. 3
D, compare lanes 5 and 6). Ca2 , a known stimulator of
calpain-mediated proteolysis, increased the amount of 16-
kD C/EBP  (Fig. 3 D, compare lanes 2 and 3); calpain in-
hibitor blocked this increase (Fig. 3 D, lanes 3 and 4). The
16-kD C/EBP  measured by Western blot analysis was
present in the nuclear fraction (Fig. 3 D, lane 5), whereas a
majority of the 37-kD C/EBP  was in the cytoplasmic
fraction (Fig. 3 D, lane 7). As a result, the ratio of inhibi-
tory to stimulatory C/EBP  in whole cell extracts is an un-
derestimate of the state of transcriptional inhibition present
in the nucleus.
The Effect of Lymphocyte Contact is Mimicked by Cross-
linking Costimulatory Molecules CD-40, VCAM, and B7.
Because macrophage-expressed costimulatory molecules
CD40, VCAM, and B7 are important mediators of lym-
phocyte–macrophage interaction, we tested whether or
not antibodies against CD-40, VCAM, and B7 would alter
C/EBP  expression. There was no change in C/EBP  ex-
pression when a combination of antibodies against CD-40,
VCAM, and B7 (stimulating antibodies) were added in the
absence of protein A/G beads (Fig. 4 A, lanes 1, 3, and 5).
When a combination of stimulating antibodies were at-
tached to a solid substrate by incubating them with agarose
protein A/G beads, macrophages markedly down-regulate
C/EBP  expression after 2 d (Fig. 4 A, lanes 4 and 6).
Goat IgG isotype control did not alter C/EBP  expression
with or without protein A/G beads (Fig. 4 A, lanes 1 and
2). The beads by themselves did not alter C/EBP  expres-
sion (unpublished data). The expression of inhibitory
C/EBP  was not significantly changed when only two of
these antibodies were used in combination (Fig. 4 B, com-
pare lane 1 with lanes 3, 5, and 7). The addition of protein
A/G beads did, however, lead to the downregulation of
Figure 2. C/EBP  expression and HIV-1 viral loads in AM after lym-
phocyte addition. (A) Western blot of whole cell extract probed with
C/EBP  polyclonal antibody. AM from an uninvolved lung segment of
an HIV-1–TB-coinfected patient (lane 1). Con A–stimulated allogenic
lymphocytes were added to the AM for 1 (lane 2) or 4 d of coculture
(lane 3). Resting syngenic lymphocytes were added for 1 (lane 4) or 4 d
(lane 5). Con A–activated lymphocytes are separated from AM by a 0.4-
 m filter insert (lane 6). AM from a lung segment involved with TB (lane
7). (B) AM from two HIV-1–infected patients with normal chest radio-
graphs after 1 d of culture (lanes 1 and 5). Activated allogenic lympho-
cytes were added for 1 (lanes 2 and 6), 4 (lanes 3 and 7), or 6 d (lane 4).
The HIV-1 viral copy number released into the cell culture supernatant
for each condition is shown in the boxes below the Western lanes.500 Contact and Cytokines Are Needed for Maximal HIV Replication
Figure 3. C/EBP  expression
in macrophages with and with-
out lymphocyte contact. (A)
EMSA of whole cell THP-1 cell
extracts with the HIV-1–LTR
NRE that contains a C/EBP
binding site. THP-1 cells after
PMA differentiation (lane 1) and
the same extract with excess-
unlabeled NRE probe (lane 2).
IFN- –treated THP-1 mac-
rophages (lane 3) followed by
coculture with activated lym-
phocytes for 1 (lane 5) and 2 d
(lane 7). IFN- –treated mac-
rophages (lane 9) and supershift-
ing with antibody to C/EBP 
(lane 10). (B) A Western blot of
whole cell extracts of IFN- –
treated THP-1 macrophages 1
(lane 1), 2 (lane 2), and 4 d (lane
3) after coculture of Con
A–stimulated allogenic lympho-
cytes. Separation of Con A–acti-
vated lymphocytes from IFN- –
treated THP-1 macrophages by a
0.4- m filter for 1 (lane 4), 2
(lane 5), and 4 d (lane 6). (C) A
Western blot of TNP-1 macrophage before (lane 1) and 2 d after the addition of purified CD4  lymphocytes (lane 2). A nuclear extract before (lane 3)
and 2 d after the addition of purified CD8  lymphocytes (lane 4). (D) NP-40 whole cell extracts made without (lane 1) and with (lane 2) calpain inhibi-
tor. Ca2  is added to the extract without (lane 3) and with (lane 4) calpain inhibitor. Nuclear extracts made with NP-40 without (lane 5) and with (lane
6) calpain inhibitor. Cytoplasmic extracts without (lane 7) and with (lane 8) calpain inhibitor. All experiments were repeated three or more times with
similar results.
Figure 4. C/EBP  expres-
sion in THP-1 macrophages af-
ter addition of antibodies. (A)
Whole cell extract of IFN- –
treated THP-1 macrophages 2 d
after goat IgG without (lane 1)
or with (lane 2) protein A/G
agarose. Affinity-purified goat
IgG specific for CD40, VCAM,
and B7-1 was added without
(lane 3) and with (lane 4) pro-
tein A/G agarose beads for 2 d.
Antibodies for B7-2 are substi-
tuted for antibodies of B7-1
without (lane 5) and with (lane 6)
protein A/G beads. (B) C/EBP 
Western of nuclear extract of
IFN- –treated THP-1 mac-
rophage (lane 1); 2 d after addi-
tion of antibodies to VCAN and
B7-1 without (lane 2) and with
(lane 3) protein A/G beads; or
antibodies to CD40 and VCAM
(lanes 4 and 5); or antibodies to
CD40 and B7-1 (lanes 6 and 7).
(C) EMSA with the HIV-1–LTR
NRE 2 d after combination of
antibodies IgG specific for
CD40, VCAM, and B7-1 without and with protein A/G beads (lanes 1 and 2). Antibodies for B7-2 are substituted for antibodies of B7-1 (lanes 3 and
4). Single antibodies to CD40, VCAM, B7-1, or B7-2 with and without protein A/G beads (lanes 5–13). All experiments were done at least three
times with similar results. (D) Coculture of IFN- –treated THP-1 macrophages with Con A activate allogenic lymphocytes. C/EBP  Western of
whole cell extracts with the addition of blocking antibodies to lymphocyte expressed CD 40 ligand (CD 154), VLA-4 (CD 49 ), and CD 28 (lane 1).
Lymphocyte addition without added antibodies (lane 2). Whole cell extracts of coculture experiments AM. Blocking added (lane 3) and no antibodies
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the 37-kD C/EBP  in this set of experiments. EMSA with
the HIV-1 LTR NRE shows similar results. Stimulating
antibodies on a solid substrate markedly reduced NRE–
protein complexes when compared with antibodies added
in solution (Fig. 4 C, compare lanes 1 and 3 with lanes 2
and 4). When single antibodies to CD-40, VCAM, B7-1,
or B7-2 were added to the THP-1 model, there was
no change in NRE–protein complexes. This was true
whether or not protein A/G beads were added (Fig. 4 C,
compare lane 5 with lanes 6–13). These data suggest that
the cross-linking of multiple macrophage-expressed co-
stimulatory molecules is required to down-regulate inhibi-
tory C/EBP  expression.
CD40 ligand, VLA-4, and CD-28 are the lymphocyte-
expressed ligands that activate macrophage-expressed CD-
40, VCAM, and B7 (16, 17). FACS® analysis showed that
CD-40 ligand, VLA-4, and CD-28 were strongly expressed
on Con A–activated lymphocytes, and that both CD-40
ligand and CD-28 were upregulated by activation (unpub-
lished data). A combination of antibodies to CD-40 ligand,
VLA-4, and CD-28 blocked the downregulation of macro-
phage 16-kD C/EBP  (Fig. 4  D, compare lane 3 with
lanes 2 and 4). This was true in both the THP-1 model and
in primary AM. Blocking occurred when lymphocytes
were activated by MHC incompatibility (Fig. 4 D, lanes
1–4) or by antibody to CD-3 (unpublished data).
Maximal HIV-1–LTR Induction Requires both Lymphocyte–
Macrophage Contact and Lymphocyte-derived Cytokines.  To
investigate the functional effects of macrophage–lympho-
cyte interaction on HIV-1 replication we used BF-24 cells,
which are THP-1 cells with an integrated HIV-1 LTR
CAT reporter construct. As shown in Fig. 5, LTR activity
increased 12.5-   1.6-fold (mean   SEM) when Con
A–activated lymphocytes were mixed with BF-24 cells.
LTR activity increased only 5.1-   1.5-fold when the acti-
vated lymphocytes were separated from the BF-24 cells
with a 0.4- m pore-size insert (P   0.01 Student’s t test
when compared with contact with Con A–stimulated lym-
phocytes), in spite of a marked elevation of IL-1  (350 pg/
ml), IL-6 (11,600 pg/ml), and TNF-  (1,000 pg/ml) in the
cell culture supernatant. Similarly, LTR activity increased
only 3.3-   1.1-fold when a combination of cross-linking
antibodies to CD-40, VCAM, and B7 were added in the
presence of protein A/G beads (P   0.01 when compared
with Con A–lymphocyte contact).
To combine the contribution of soluble factors and con-
tact, activated lymphocytes were added to the upper cham-
ber of an insert well to provide both lymphocyte-derived
soluble factors, and stimulatory antibodies on a solid sub-
strate were added to BF-24 cells in the lower chamber to
provide contact-mediated stimuli. Maximal LTR activa-
tion was restored (14.6-   0.7-fold increase) when BF-24
cells were exposed to lymphocyte-soluble factors and con-
tact with antibodies to CD40, VCAM, and B7 on protein
A/G beads. When IL-1  (350 pg/ml), IL-6 (11,600 pg/
ml), and TNF-  (1,000 pg/ml) were added to BF-24 cells
with cross-linking antibodies to CD40, VCAM, and B7,
HIV-1–LTR activity was markedly increased (8.1-   1-fold).
This demonstrates that both contact and soluble factors are
necessary and sufficient to produce the level of LTR stimu-
lation observed when lymphocytes and macrophages are
cocultured.
The NF- B transcription factors are excellent candidates
to mediate the effects of soluble factor(s) released by lym-
phocytes. We used EMSA to measure NF- B DNA bind-
ing activity in cocultured cells. THP-1 cells that differenti-
ated with PMA have no specific NF- B DNA binding
activity (Fig. 6 A, lane 1). The addition of IFN-  produces
a slight increase in the amount of NF- B DNA binding ac-
tivity (Fig. 6 A, lane 3). The addition of activated lympho-
cytes produced a marked increase in NF- B DNA binding
activity after 1 or 2 d of coculture (Fig. 6 A, lanes 5 and 7).
This DNA binding activity is specific for the NF- B site
because excess, unlabeled oligonucleotide competes with
Figure 5. HIV-1 LTR promoter in IFN- –treated
THP-1 macrophages. From left to right, HIV-1–LTR CAT
production 2 d after the addition of: Con A–activated allo-
genic lymphocytes; activated lymphocytes separated from
macrophages with a 0.4- m filter; antibodies to CD-40,
VCAM, and B7 in the presence of protein A/G beads; acti-
vated lymphocytes added to the upper chamber of an insert
well and stimulatory antibodies with protein A/G beads
added to the lower chamber; and stimulatory antibodies at-
tached to protein A/G beads in addition to IL-1  (350 pg/
ml), IL-6 (11,600 pg/ml), and TNF-  (1,000 pg/ml).502 Contact and Cytokines Are Needed for Maximal HIV Replication
the complex (Fig. 6 A, lanes 4, 6, and 8). Antibody to the
p50 or p65 isoform of NF- B supershifts the complex (Fig.
6 A, compare lane 9 with lanes 10 and 11). When lympho-
cytes are separated from the THP-1 cells with an insert,
there is an increase in NF- B binding activity similar to di-
rect contact of lymphocytes and macrophages (Fig. 6 A,
lane 12). This complex also contains NF- B p50 and p65
(Fig. 6 A, lanes 13 and 14). These data demonstrate that
lymphocyte-derived soluble factors are capable of activat-
ing NF- B in this system. In an independent experiment,
the soluble factors were more effective than contact in
inducing NF- B (Fig. 6 A, compare lanes 15 and 16),
whereas protein A/G beads with stimulatory antibodies to
CD-40, VCAM, and B7, failed to induce NF- B (Fig. 6
A, lane 17).
Coculture of primary AM of an HIV-1–infected patient
without lung disease and without TB was used to validate
THP-1 cells as a model system. In the absence of stimula-
tion, NF- B was not induced in AM (Fig. 6 B, lanes 1
and 2). The addition of resting syngenic lymphocytes did
not induce NF- B DNA binding activity at 1 or 4 d (Fig.
6 B, lanes 3–6). The addition of activated allogenic lym-
phocytes did lead to the induction of NF- B (Fig. 6 B,
lanes 7–10). The uninvolved lung segment of a patient
with TB had little NF- B (Fig. 6 B, lane 11), whereas
there was marked upregulation of NF- B in the involved
lung segment from the same patient (Fig. 6 B, lane 13).
Upregulation of NF- B was observed in the involved
lung segment of two additional patients (unpublished
data). Competition with excess unlabeled oligonucleotide
demonstrated a nonspecific band in the resting and unin-
volved AM preparations. The similarity of these results
with primary and transformed cells supports the use of
THP-1 cells in this system.
Discussion
HIV-1 replication in AM is normally suppressed with
fewer than 1 in 10,000 cells harboring provirus and little
or no HIV-1 present in bronchoalveolar lining fluid (1).
During TB there is a marked increase in HIV-1 replication
in the lung with the AM as the major source (1–3). The
likely source of this virus is latently infected cells that re-
side in the lung before the occurrence of TB (1, 2). TB ac-
celerates AIDS mortality even when the TB is appropri-
ately treated (4). The enhanced viral replication and
increased viral mutation likely underlies the accelerated
course of AIDS observed in TB-coinfected patients. High
levels of HIV-1 replication in vivo are associated with the
loss of an inhibitory C/EBP  transcription factor and the
increase of NF- B (11). Attempts to model this state of
macrophage activation by infecting cells in vitro with M.
tuberculosis did not reproduce the changes in C/EBP  ex-
pression nor viral replication observed in patients with pul-
monary TB (14). We now report that the addition of acti-
vated lymphocytes to macrophages reproduces the state of
activation observed during TB. There is a loss of inhibi-
tory C/EBP , an activation of NF- B, and an increase in
HIV-1 replication. Investigation of this model further
demonstrated that maximal transcriptional activation of the
HIV-1 LTR is a two-step process that requires both con-
tact and soluble factors. The contact leads to a loss of in-
Figure 6. NF- B DNA binding activity in THP-1
macrophages and AM after lymphocyte addition.
(A) EMSA with an oligonucleotide containing an
NF- B binding site in whole cell, extracts THP-1
cells after PMA differentiation (lanes 1), the addi-
tion of IFN-  (lane 3), and the addition of lym-
phocytes for 1 (lane 5) and 2 d (lane 7). Excess un-
labeled oligonucleotide was added to the extract in
the preceding lane (lanes 2, 4, 6, and 8). EMSA
with nuclear extracts from an independent experi-
ment 2 d after coculture of THP-1 macrophages
with stimulated allogeneic lymphocytes (lane 9) su-
pershifted with anti-p65 NF- B antibody (lane 10),
or anti-p50 NF- B antibody (lane 11). EMSA of
nuclear extracts 2 d after separation of activated
lymphocytes from macrophages with a 0.4- m filter
insert (lane 12), supershifted with anti-p65 NF- B
antibody (lane 13), or anti-p50 NF- B antibody
(lane 14). An independent experiment with whole
cell extracts 2 d after addition of lymphocytes (lane
15) or separation of activated lymphocytes from
macrophages by a 0.4- m filter insert (lane 16), or
2 d after antibodies to CD-40, VCAM, and B7 in
the presence of protein A/G beads (lane 17). Ex-
periments were repeated three or more times with
similar results. (B) EMSA of whole cell extracts
from AM after 1 d of culture without treatment (lane 1). Extracts from the same patient treated with 1 (lane 3) and 4 d (lane 5) of coculture with resting
syngenic lymphocytes, and 1 (lane 7) and 4 d (lane 9) of coculture with Con A–activated allogeneic lymphocytes. EMSA of BAL from an HIV-1–TB-
coinfected patient with uninvolved lung segment (lane 11) and involved lung segment (lane 13). Excess unlabeled oligonulceotide was added to the ex-
tract (lanes 2, 4, 6, 8, 10, 12, and 14).503 Hoshino et al.
hibitory C/EBP  that derepress the HIV-1 LTR, whereas
soluble factors produce NF- B activation that enhances
HIV-1–LTR transcription.
THP-1 cells were used to investigate the mechanisms
underlying the contact-mediated loss of inhibitory
C/EBP . THP-1 cells are a human monocytic cell line
that are similar to AM when they have been differentiated
with PMA and stimulated with low-dose IFN- ; both ex-
press inhibitory C/EBP  and repress HIV-1 replication.
C/EBP sites in the HIV-1 LTR are required for HIV-1
replication in macrophages, but not in lymphocytes (9).
C/EBP  is the predominant C/EBP family member ex-
pressed in macrophages (5, 11), and overexpression of in-
hibitory 16-kD C/EBP  strongly inhibits HIV-1–LTR
transcription in model systems (12). TB leads to the loss of
inhibitory C/EBP , which derepresses the HIV-1 LTR
(11). Both Western blots of BAL cells and immunohis-
tochemistry of lung sections confirm a significant reduction
of C/EBP  expression in lung segments involved with TB.
This is particularly true of short-form C/EBP  that is lo-
calized in the nucleus. The expression of cytoplamic long
form is maintained in a number of conditions, raising the
possibility of nonnuclear functions of this protein in macro-
phages. The regulation of short-form C/EBP  is particu-
larly important because it is a dominant-negative transcrip-
tion factor (6) and a strong repressor of HIV-1 transcription
in macrophages (12).
Mechanisms that produce inhibitory C/EBP  are not
fully understood. Genetic evidence using expression con-
structs suggests that inhibitory C/EBP  is produced by
translational initiation at an internal AUG start site (6, 19,
20). Proteolysis occurring in vivo has also been proposed
as a mechanism for short-form production (21). Concern
has been raised, however, that production of inhibitory
C/EBP  occurs during the extraction procedure and is
mediated by a calpain protease (17). The protease is inhib-
ited by NP-40 detergent and calpain inhibitor and is en-
hanced by Ca2  (18). All of the cell extracts presented in
this investigation were made with NP-40 to prevent a
proteolytic artifact. The addition of calpain inhibitor to
the NP-40 extraction buffer did not affect the amount of
inhibitory C/EBP . The addition of Ca2  to the extrac-
tion buffer increased the amount of inhibitory C/EBP ,
demonstrating that a Ca2 -responsive protease was present.
Calpain inhibitor was effective in blunting the increase of
inhibitory C/EBP  after the addition of Ca2  to the ex-
traction buffer, which suggests that although a calpain-like
protease is present in the THP-1 macrophages extracts,
it did not contribute to the amount of 16-kD C/EBP 
observed. These data strongly support the conclusion
that under the conditions used in this investigation, the
amount of 16-kD C/EBP  provides a relevant measure
of the inhibition of promoters with C/EBP binding
sites.
Adding activated lymphocytes to macrophages over-
comes the transcriptional repression of the HIV-1 LTR in-
duced by low-dose IFN- . This interaction is not MHC
restricted and occurs with both CD4  and CD8  lympho-
cyte subsets. HIV-1–TB-coinfected patients have a CD8 
lymphocytic alveolitis (22). Our finding that CD8  lym-
phocyte subsets are capable of downregulating both
C/EBP  isoforms fits with the observation that in some
patients no C/EBP  is expressed in involved lung seg-
ments (11). Lymphocytes activated by MHC incompatibil-
ity, Con A, or anti-CD3 antibody abolished the expression
of inhibitory C/EBP  in both AM and THP-1 macro-
phages. AM cocultured for 4 d with resting syngenic lym-
phocytes had stable expression of both stimulatory and in-
hibitory C/EBP , indicating that the changes in C/EBP 
produced by activated lymphocytes were not an artifact of
ex vivo tissue culture. When allogenic lymphocytes from
an HIV-1–negative donor are added to AM from HIV-1–
infected patients, HIV-1 replication increases and inhibi-
tory C/EBP  is lost. The increased HIV-1 replication may
be due in part to HIV-1 infection and replication in the
added lymphocytes. However, the 12.5-fold increase in
HIV-1–LTR transcriptional activity when lymphocytes are
added to THP-1 macrophages, suggests that transcriptional
activation of the LTR in macrophages significantly con-
tributes to the increased viral replication observed in the ex
vivo coculture experiments.
When the lymphocytes and macrophages were separated
by a 0.4- m insert, activated lymphocytes failed to reduce
inhibitory C/EBP  expression in either AM or the THP-1
cell model. Functionally, HIV-1–LTR activation in mac-
rophages is reduced by 66% when macrophages are sepa-
rated from activated lymphocytes. This demonstrates that
direct contact between lymphocytes and macrophages is
required for downregulation of inhibitory C/EBP  and
maximal induction of the HIV-1 LTR in macrophages.
These findings are consistent with the observation that the
membrane fraction of activated lymphocytes enhances
HIV-1 replication in macrophages (16).
HIV-1 viral load and TNF-  production are strongly
correlated (r2   0.95) in involved lung segments of AIDS
patients with pulmonary TB (2). One explanation of these
findings is that the HIV-1 LTR and the TNF-  promoter
are coordinately regulated in the lung during opportunistic
infections. The TNF-  promoter, like the HIV-1 LTR,
contains C/EBP sites. One of the consequences of express-
ing the inhibitory C/EBP  in macrophages is that proin-
flammatory cytokine production is strongly suppressed (7).
Similar to the observations that maximal induction of the
HIV-1 LTR requires contact, maximal induction of
TNF-  requires contact between activated lymphocytes
and brain macrophages (23, 24). The stimulation of
TNF-  is due in part to lymphocyte-expressed CD-40
ligand, VLA-4, and CD-28 binding to macrophage-
expressed CD-40, VCAM, and B7.
Antibodies binding macrophage costimulatory receptors
CD-40, VCAM, and B7 were used to mimic the effect of
lymphocyte contact. To further enhance the cross-linking
effect of the antibodies, the Fc portion of these antibodies
was attached to protein A/G beads. Expression of inhibi-
tory C/EBP  is lost only when a combination of affinity-
purified antibodies to CD-40, VCAM, and B7-1 or B7-2504 Contact and Cytokines Are Needed for Maximal HIV Replication
are attached to agarose beads and presented to macrophages.
The specific effect of the stimulating antibody–agarose bead
combination is demonstrated by the stable expression of
C/EBP  after the addition of goat IgG isotype-control an-
tibody, either in the presence or absence of protein A/G
agarose beads. These findings show that lymphocyte-
derived soluble factors are not required to abolish in-
hibitory C/EBP  expression, and antibodies to CD-40,
VCAM, and B7 on a solid substrate, are able to substitute
for lymphocyte contact.
C/EBP  expression is unchanged when single antibod-
ies to CD-40, VCAM, and B7-1 or B7-2 are attached to
agarose beads and presented to macrophages. This demon-
strates that multiple costimulatory receptors must be cross-
linked before the signal to reduce C/EBP  expression is
transduced. This suggests that when antibodies are oriented
on a solid substrate they are more effective in producing
signal transduction, possibly because all costimulatory mol-
ecules are cross-linked at the point of contact between the
bead and the macrophage.
Lymphocyte-expressed CD-40 ligand, VLA-4, and
CD-28 bind macrophage-expressed CD-40, VCAM, and
B7. Activated lymphocytes expressed all three ligands. An-
tibodies directed against lymphocyte-expressed ligands
were tested for the ability to block downregulation of in-
hibitory C/EBP  expression. A mixture of antibodies to
lymphocyte-expressed CD-40 ligand, VLA-4, and CD-28
blocked the downregulation of C/EBP  in both AM and
THP-1 macrophages. These antibodies were capable of
blocking the effect of activated lymphocytes. These data
support a model in which multiple lymphocyte-costimula-
tory molecules must interact with multiple macrophage-
costimulatory molecules in order to down-regulate inhibi-
tory C/EBP  (Fig. 7).
Whereas lymphocyte-derived soluble factors are unable
to down-regulate inhibitory C/EBP , they are able to par-
tially activate the HIV-1 LTR. There are many cytokines
released in this system including high levels of IL-1 , IL-6,
and TNF- . All of these cytokines are capable of activating
NF- B, and the binding of NF- B to the HIV-1 LTR
strongly stimulates the HIV-1 LTR (12, 13). EMSA dem-
onstrated that NF- B p50 and p65 were activated in cocul-
ture experiments. In addition to activation of NF- B,
lymphocyte-derived soluble factors alter macrophage mor-
phology and activate other DNA binding activities (unpub-
lished data). The activation of NF-  B, and possibly other
transcription factors by soluble factors, accounts for the par-
tial activation of the HIV-1 LTR observed in experiments
in which activated lymphocytes are separated from macro-
phages by an insert.
The combination of lymphocyte-derived soluble factors
with contact-mediated stimuli provided by antibodies to
CD-40, VCAM, and B7-1 or B7-2, restored maximal
HIV-1–LTR activity. The addition of IL-1 , IL-6, and
TNF-  at concentrations found in coculture experi-
ments to THP-1 macrophages with cross-linked CD-40,
VCAM, and B7, also markedly increased HIV-1–LTR ac-
tivity. This leads to a model in which two steps are re-
quired for full activation of the HIV-1 LTR. Contact leads
to the loss of inhibitory C/EBP  derepressing the HIV-1
LTR, whereas soluble factors leads to the activation of
NF- B. Neither stimulus is sufficient for full induction of
the HIV-1 LTR.
Upregulation of the HIV-1 LTR in macrophage by acti-
vated lymphocytes represents another example of HIV-1
usurping normal immune regulation in order to enhance its
replication. Granulomatus inflammation is highly destruc-
tive to lung architecture. Many of the macrophage media-
tors of cellular immunity have C/EBP sites in their pro-
moters, and inhibition of these proinflammatory pathways
might be important for maintaining lung homeostasis in the
absence of infection. The requirement for lymphocyte
contact to produce the state of activation seen in TB, likely
limits the tissue destruction observed in granulomatous in-
flammation to areas where lymphocytes are activated by
the presence of antigen stimulation.
We would like to thank Richard Pine (Public Health Research In-
stitute, New York, NY), Nobukazu Watanabe, and Tetsuya Naka-
mura (University of Tokyo, Department of Infectious Diseases, In-
stitute of Medical Science, Tokyo, Japan) for technical advice.
This work is supported by MO1 RR00096, HL57879,
HL59832, HL62055 American Lung Association, New York Uni-
versity Center for AIDS Research, and the Japanese Foundation for
AIDS Prevention.
Submitted: 20 September 2001
Revised: 13 December 2001
Accepted: 8 January 2002
Figure 7. A model of lymphocyte–macrophage interaction during the
cellular immune response leading to increased HIV-1 replication. Contact
leads to the loss of inhibitory C/EBP , derepressing the 5  HIV-1 LTR
whereas soluble factors activate NF- B, which enhances HIV-1 replication.505 Hoshino et al.
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